AMIX AUTONOMIX MEDICAL INC

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

THE WOODLANDS, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the on Tuesday, March 18, 2025 at 7:35 AM PT.

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

The in-person presentation will be accessible to those registered to attend the event. For more information, please visit the .

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit and connect with the Company on , , and .

Investor and Media Contact

JTC Team, LLC

Jenene Thomas

908.824.0775



EN
26/02/2025

Underlying

AMIXAUTONOMIX MEDICAL INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Autonomix Medical, Inc. to Present at the Webull Financial Corporate C...

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech – Live video webcast on Thursday, August 21st at 2:20 PM ET THE WOODLANDS, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will present at the being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Thursday, August 21, 2025 at 2:20 PM ET Presenter: Registration Link: About Webull Financi...

August 15, 2025 1 EN
 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravas...

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption (“IDE”), and if approved, the commencement of U.S. clinical trials to support a De Novo FDA application THE WOODLANDS, TX, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to adva...

August 14, 2025 1 EN
 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Y...

Autonomix Medical, Inc. Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference – Video webcast now available on-demand  THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that , participated in the . For the event, Mr. Hauser dove deeper into his dedication to the Company, how he got to where he is today, and provided insight int...

July 22, 2025 1 EN
 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Pr...

Autonomix Medical, Inc. Exercise of Warrants for $2.5 Million Gross Proceeds THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise (or prepayment of the exercise price) of certain outstanding warrants to purchase up to an aggregate of 1,477,596 shares of common stock of the Company originally issued in November 2024 at a reduced exercise pri...

July 22, 2025 1 EN
 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally I...

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, July 21, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advanci...

July 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch